Silvy Gabel
Katholieke Universiteit Leuven
36 Papers
26 Citations
Silvy Gabel is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Biomarker discovery. The author has an hindex of 11, co-authored 28 publications. Previous affiliations of Silvy Gabel include Maastricht University & University of Amsterdam.
Chat about Author
Papers
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
Daniel Stamate,Daniel Stamate,Min Kim,Petroula Proitsi,Sarah Westwood,Alison L. Baird,Alejo J. Nevado-Holgado,Abdul Hye,Isabelle Bos,Isabelle Bos,Stephanie J.B. Vos,Rik Vandenberghe,Charlotte E. Teunissen,Mara ten Kate,Mara ten Kate,Philip Scheltens,Silvy Gabel,Silvy Gabel,Karen Meersmans,Olivier Blin,Jill C. Richardson,Ellen Elisa De Roeck,Ellen Elisa De Roeck,Sebastiaan Engelborghs,Sebastiaan Engelborghs,Kristel Sleegers,Régis Bordet,Lorena Ramit,Petronella Kettunen,Magda Tsolaki,Frans R.J. Verhey,Daniel Alcolea,Alberto Lleó,Gwendoline Peyratout,Mikel Tainta,Peter Johannsen,Yvonne Freund-Levi,Yvonne Freund-Levi,Lutz Frölich,Valerija Dobricic,Giovanni B. Frisoni,José Luis Molinuevo,José Luis Molinuevo,Anders Wallin,Julius Popp,Julius Popp,Pablo Martinez-Lage,Lars Bertram,Lars Bertram,Kaj Blennow,Kaj Blennow,Henrik Zetterberg,Johannes Streffer,Pieter Jelle Visser,Pieter Jelle Visser,Simon Lovestone,Simon Lovestone,Cristina Legido-Quigley,Cristina Legido-Quigley +58 more
TL;DR: This work sets out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers to capture the metabolic complexity in Alzheimer Disease.
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
Min Kim,Stuart G. Snowden,Tommi Suvitaival,Adnan Ali,David J. Merkler,Tahmina Ahmad,Sarah Westwood,Alison L. Baird,Petra Proitsi,Alejo J. Nevado-Holgado,Abdul Hye,Isabelle Bos,Stephanie J.B. Vos,Rik Vandenberghe,Charlotte E. Teunissen,Mara ten Kate,Philip Scheltens,Silvy Gabel,Karen Meersmans,Olivier Blin,Jill C. Richardson,Ellen De Roeck,Kristel Sleegers,Régis Bordet,Lorena Rami,Petronella Kettunen,Magda Tsolaki,Frans R.J. Verhey,Isabel Sala,Alberto Lleó,Gwendoline Peyratout,Mikel Tainta,Peter Johannsen,Yvonne Freund-Levi,Lutz Frölich,Valerija Dobricic,Sebastiaan Engelborghs,Giovanni B. Frisoni,José Luis Molinuevo,Anders Wallin,Julius Popp,Pablo Martinez-Lage,Lars Bertram,Frederik Barkhof,Nicholas J. Ashton,Kaj Blennow,Henrik Zetterberg,Johannes Streffer,Pieter Jelle Visser,Simon Lovestone,Cristina Legido-Quigley +50 more
TL;DR: This data indicates that metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers may be linked to brain pathology in patients with AD.
MRI predictors of amyloid pathology: Results from the EMIF-AD Multimodal Biomarker Discovery study
Mara ten Kate,Alberto Redolfi,Enrico Peira,Isabelle Bos,Stephanie J.B. Vos,Rik Vandenberghe,Silvy Gabel,Jolien Schaeverbeke,Philip Scheltens,Olivier Blin,Jill C. Richardson,Régis Bordet,Anders Wallin,Carl Eckerström,José Luis Molinuevo,Sebastiaan Engelborghs,Christine Van Broeckhoven,Pablo Martinez-Lage,Julius Popp,Julius Popp,Magdalini Tsolaki,Frans R.J. Verhey,Alison L. Baird,Cristina Legido-Quigley,Lars Bertram,Lars Bertram,Lars Bertram,Valerija Dobricic,Henrik Zetterberg,Simon Lovestone,Johannes Streffer,Silvia Bianchetti,Gerald Novak,Jérôme Revillard,Mark Forrest Gordon,Zhiyong Xie,Viktor Wottschel,Giovanni B. Frisoni,Pieter Jelle Visser,Pieter Jelle Visser,Frederik Barkhof +40 more
TL;DR: An automated classifier based on clinical, imaging and APOE ε4 data can identify the presence of amyloid pathology with a moderate level of accuracy and could be used in clinical trials to pre-screen subjects for anti-amyloid therapies.
81
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.
Steffi De Meyer,Jolien Schaeverbeke,Jolien Schaeverbeke,Inge M.W. Verberk,Benjamin Gille,Benjamin Gille,Maxim De Schaepdryver,Maxim De Schaepdryver,Emma Susanne Luckett,Emma Susanne Luckett,Silvy Gabel,Silvy Gabel,Rose Bruffaerts,Rose Bruffaerts,Kimberley Mauroo,Elisabeth H. Thijssen,Erik Stoops,Hugo Vanderstichele,Charlotte E. Teunissen,Rik Vandenberghe,Rik Vandenberghe,Koen Poesen,Koen Poesen +22 more
TL;DR: ELISA and SIMOA demonstrated equivalent performances in detecting cerebral amyloidosis through plasma Aβ 1–42 /Aβ 1-40 , both with high negative predictive values, making them equally suitable non-invasive prescreening tools for clinical trials by reducing the number of necessary PET scans for clinical trial recruitment.
Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
Shengjun Hong,Dmitry Prokopenko,Valerija Dobricic,Fabian Kilpert,Isabelle Bos,Isabelle Bos,Stephanie J.B. Vos,Betty M. Tijms,Ulf Andreasson,Ulf Andreasson,Kaj Blennow,Kaj Blennow,Rik Vandenberghe,Isabelle Cleynen,Silvy Gabel,Jolien Schaeverbeke,Philip Scheltens,Charlotte E. Teunissen,Ellis Niemantsverdriet,Sebastiaan Engelborghs,Sebastiaan Engelborghs,Giovanni B. Frisoni,Olivier Blin,Jill C. Richardson,Régis Bordet,José Luis Molinuevo,Lorena Rami,Petronella Kettunen,Petronella Kettunen,Anders Wallin,Alberto Lleó,Isabel Sala,Julius Popp,Julius Popp,Gwendoline Peyratout,Pablo Martinez-Lage,Mikel Tainta,Richard Dobson,Cristina Legido-Quigley,Cristina Legido-Quigley,Kristel Sleegers,Christine Van Broeckhoven,Mara ten Kate,Frederik Barkhof,Henrik Zetterberg,Simon Lovestone,Johannes Streffer,Michael Wittig,Andre Franke,Rudolph E. Tanzi,Pieter Jelle Visser,Lars Bertram,Lars Bertram +52 more
TL;DR: This study represents a detailed first account of GWAS analyses on CSF-Aβ and -tau-related traits in the EMIF-AD MBD dataset and reveals that AD risk variants only explain a small fraction of CSF biomarker variability.